Browse LGALS1

Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF00337 Galactoside-binding lectin
Function

Lectin that binds beta-galactoside and a wide array of complex carbohydrates. Plays a role in regulating apoptosis, cell proliferation and cell differentiation. Inhibits CD45 protein phosphatase activity and therefore the dephosphorylation of Lyn kinase. Strong inducer of T-cell apoptosis.

> Gene Ontology
 
Biological Process GO:0001678 cellular glucose homeostasis
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002313 mature B cell differentiation involved in immune response
GO:0002317 plasma cell differentiation
GO:0002335 mature B cell differentiation
GO:0002366 leukocyte activation involved in immune response
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0010721 negative regulation of cell development
GO:0010810 regulation of cell-substrate adhesion
GO:0010812 negative regulation of cell-substrate adhesion
GO:0010975 regulation of neuron projection development
GO:0010977 negative regulation of neuron projection development
GO:0019058 viral life cycle
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030260 entry into host cell
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031345 negative regulation of cell projection organization
GO:0031589 cell-substrate adhesion
GO:0033500 carbohydrate homeostasis
GO:0033555 multicellular organismal response to stress
GO:0034109 homotypic cell-cell adhesion
GO:0034110 regulation of homotypic cell-cell adhesion
GO:0034112 positive regulation of homotypic cell-cell adhesion
GO:0034117 erythrocyte aggregation
GO:0034118 regulation of erythrocyte aggregation
GO:0034120 positive regulation of erythrocyte aggregation
GO:0034284 response to monosaccharide
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042493 response to drug
GO:0042593 glucose homeostasis
GO:0042692 muscle cell differentiation
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043900 regulation of multi-organism process
GO:0043902 positive regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044409 entry into host
GO:0045445 myoblast differentiation
GO:0045665 negative regulation of neuron differentiation
GO:0045785 positive regulation of cell adhesion
GO:0046596 regulation of viral entry into host cell
GO:0046598 positive regulation of viral entry into host cell
GO:0046718 viral entry into host cell
GO:0048524 positive regulation of viral process
GO:0048678 response to axon injury
GO:0050768 negative regulation of neurogenesis
GO:0050792 regulation of viral process
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051701 interaction with host
GO:0051806 entry into cell of other organism involved in symbiotic interaction
GO:0051828 entry into other organism involved in symbiotic interaction
GO:0051961 negative regulation of nervous system development
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071322 cellular response to carbohydrate stimulus
GO:0071326 cellular response to monosaccharide stimulus
GO:0071331 cellular response to hexose stimulus
GO:0071333 cellular response to glucose stimulus
GO:0071407 cellular response to organic cyclic compound
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903900 regulation of viral life cycle
GO:1903902 positive regulation of viral life cycle
Molecular Function GO:0001948 glycoprotein binding
GO:0030246 carbohydrate binding
GO:0030395 lactose binding
GO:0043236 laminin binding
GO:0048030 disaccharide binding
GO:0050840 extracellular matrix binding
GO:0070492 oligosaccharide binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LGALS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LGALS1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
22569001Gastric CarcinomaInhibit immunity (T cell function)Our findings suggested that FoxP3 expression by tumour cells might have important roles in immune escape of gastric carcinoma, and be associated with the malignant potential of scirrhous gastric carcinoma. Indoleamine-2,3-dioxygenase and galectin-1, key effectors of Treg-mediated immunosuppression, were downregulated by FoxP3 knockdown.
28512172Prostate CarcinomaInhibit immunityTo gain clinical insight, we used prostate cancer patient-derived samples in our studies to assess the expression of HO-1 and other relevant genes.Results:Conditioning resulted in increased tumor latency and decreased initial growth rate. Tumors from hemin-conditioned mice showed reduced expression of galectin-1 (Gal-1), key modulator of tumor angiogenesis and immunity, evidencing persistent remodeling of the microenvironment.
23444403Hodgkin LymphomaInhibit immunity (T cell function)Hodgkin lymphoma (HL) Reed-Sternberg cells overexpress and secrete Gal1, which selectively kills T helper (Th)1 and Th17 cells and cytotoxic T cells and promotes the immunosuppressive Th2/regulatory T-cell-predominant HL microenvironment.
21191065Lung CarcinomaInhibit immunity (T cell function)We have shown that galectin-1 is highly expressed in lung cancer cell lines, together with the serum and surgical samples from lung cancer patients. Functionally, lung cancer-derived galectin-1 has been shown to alter the phenotypes of monocyte-derived DCs (MdDCs) and impair alloreactive T cell response, concomitant with the increase of CD4(+)CD25(+)FOXP3(+) regulatory T cells. The regulatory effect of galectin-1 is mediated, in part, through its ability to induce, in an Id3 (inhibitor of DNA binding 3)-dependent manner, the expression of IL-10 in monocytes and MdDCs. Of note, significant upregulation of IL-10 was seen in tumor-infiltrating CD11c(+) DCs in human lung cancer samples.
24812270Pancreatic Ductal AdenocarcinomaInhibit immunityGenetic ablation of Gal1 in a mouse model of PDAC (EIa-myc mice) dampened tumor progression by inhibiting proliferation, angiogenesis, desmoplasic reaction and by stimulating a tumor-associated immune response, yielding a 20% increase in relative lifesplan. Cellular analyses in vitro and in vivo suggested these effects were mediated through the tumor microenvironment. Mechanistic investigations revealed that Gal1 promoted Hedgehog pathway signaling in PDAC cells and stromal fibroblasts as well as in Ela-myc tumors.
25038230gliomaInhibit immunityOur findings suggest that galectin-1 suppression in human glioma could improve patient survival by restoring NK immune surveillance that can eradicate glioma cells
23929302Glioblastoma; GliomaInhibit immunity (T/NK cell function); immunotherapy targetWe demonstrated that the absence of tumor-derived but not of host-derived galectin-1 significantly prolonged the survival of glioma-bearing mice as such and in combination with dendritic cell (DC)-based immunotherapy. Both flow cytometric and pathological analysis revealed that the silencing of glioma-derived galectin-1 significantly decreased the amount of brain-infiltrating macrophages and myeloid-derived suppressor cells (MDSC) in tumor-bearing mice. Furthermore, the prolonged survival observed in untreated and DC-vaccinated glioma-bearing mice upon the silencing of tumor-derived galectin-1 strongly suggest that the in vivo targeting of tumor-derived galectin-1 might offer a promising and realistic adjuvant treatment modality in patients diagnosed with GBM.
22020795NeuroblastomaInhibit immunityNeuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Human and mouse NB cells express and secrete Gal-1, which negatively regulates T cell and dendritic cell function. Immunohistochemical analysis revealed a six- to tenfold increase in the frequency of CD4+ and CD8+ T cells infiltrating tumors from mice receiving knockdown transfectants. Finally, supernatants of NXS2/H or NXS2 cells suppressed dendritic cell (DC) maturation and induce T cell apoptosis, whereas these effects were only marginal on DCs and T cells exposed to supernatants from NXS2/L cells.
17670934Hodgkin LymphomaInhibit immunityThe AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. In cocultures of activated T cells and Hodgkin cell lines, RNAi-mediated blockade of RS cell Gal1 increased T cell viability and restored the Th1/Th2 balance. In contrast, Gal1 treatment of activated T cells favored the secretion of Th2 cytokines and the expansion of CD4+CD25high FOXP3+ Treg cells. These data directly implicate RS cell Gal1 in the development and maintenance of an immunosuppressive Th2/Treg-skewed microenvironment in cHL and provide the molecular basis for selective Gal1 expression in RS cells.
25189484lung carcinoma; Head and Neck CarcinomaInhibit immunityRadiotherapy-related systemic lymphopenia appeared to be mediated by radiotherapyinduced tumor Gal-1 secretion that could lead to tumor progression through intratumoral immune suppression and enhanced angiogenesis.
23204230Breast CarcinomaInhibit immunityTaken together, our results offer a preclinical proof of concept that therapeutic targeting of Gal1 can overcome breast cancer-associated immunosuppression and can prevent metastatic disease.
21782419pancreatic carcinomaInhibit immunityPSCs that overexpressed Galectin-1 induced apoptosis of CD4(+) T cells (p < 0.01) and CD8(+) T cells (p < 0.05) significantly, compared to normal PSCs. Knockdown of Galectin-1 in PSCs increased CD4(+) T cell (p < 0.01) and CD8(+) T cell viability (p < 0.05). Supernatants from T cells cocultured with PSCs that overexpressed Galectin-1 contained significantly increased levels of Th2 cytokines (IL-4 and IL-5, p < 0.01) and decreased Th1 cytokines (IL-2 and INF-gamma, p < 0.01).
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LGALS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LGALS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.8760.0467
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0350.846
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7450.838
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4630.442
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0420.638
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2730.927
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0640.929
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.8210.726
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7110.791
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.110.974
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.2530.961
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2870.0794
> Mutation difference between responders and non-responders
 

There is no record.
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LGALS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LGALS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LGALS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LGALS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LGALS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LGALS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLGALS1
Namelectin, galactoside-binding, soluble, 1
Aliases galectin 1; GAL1; 14 kDa laminin-binding protein; 14 kDa lectin; HBL; HLBP14; HPL; S-Lac lectin 1; beta-gala ......
Chromosomal Location22q13.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LGALS1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LGALS1.
ID Name Drug Type Targets #Targets
DB03345Beta-MercaptoethanolSmall MoleculeGLO1, LGALS1, PNPO, SCMH1, SERPINA15
DB04396ThiodigalactosideSmall MoleculeLGALS1, NCAN2
DB044471,4-DithiothreitolSmall MoleculeALDH1A1, AXIN1, CAMK2A, GSTZ1, HMGCR, LGALS1, MSRA, PPIB, TPI1, TR ......10
DB11638ArtenimolSmall MoleculeACTG1, ALB, ALDH7A1, ALDOA, ANXA2, ATP5A1, ATP5L, ATP5O, CAST, CCT ......79